key: cord-0330160-q2pjhmb9 authors: Gao, Fei; Lin, Xiaohe; He, Linling; Wang, Ruoke; Wang, Han; Shi, Xuanling; Zhang, Fuchun; Yin, Chibiao; Zhang, Linqi; Zhu, Jiang; Yu, Lei title: Development of a potent and protective germline-like antibody lineage against Zika virus in a convalescent human date: 2019-06-05 journal: bioRxiv DOI: 10.1101/661918 sha: d05684da9bd654a6ae90f72b1049661636d3192d doc_id: 330160 cord_uid: q2pjhmb9 Zika virus (ZIKV) specific neutralizing antibodies hold a great promise for antibody-based interventions and vaccine design against ZIKV infection. However, their development in infected patients remain unknown. Here, we report on the dynamic development of a potent and protective ZIKV-specific human antibody ZK2B10 initially isolated from a ZIKV convalescent individual using next-generation sequencing (NGS). The unbiased repertoire analysis showed dramatic changes in many families of heavy and light chain variable regions. However, lineage tracing of ZK2B10 revealed limited somatic hypermutation throughout the 12 months since the onset of symptom. In particular, NGS-derived germline-like somatic variants neutralized and protected mice from lethal challenge of ZIKV without detectable cross-reactivity with Dengue virus (DENV). Site-directed mutagenesis identified two residues within λ chain, N31 and S91 that are essential to the functional maturation. The dynamic features unveiled here will assist us to better understand the pathogenesis of ZIKV infection and inform rational design of vaccines. Author summary Recently emerged ZIKV is associated with severe neurological complications such as Guillain–Barré syndrome in adults and congenital microcephaly in newborns. No ZIKV-specific therapeutics or vaccines are currently available. We and others have identified a number of neutralizing antibodies capable of protecting experimental animals from ZIKV infection. However, the development of these potent antibodies during ZIKV natural infection remains unknown. Here, we report on the longitudinal analysis of one such antibody ZK2B10 using next-generation sequencing (NGS), bioinformatics and functional analysis. We found that the ZK2B10 germline-like antibodies possess strong neutralizing activity in vitro and impressive protectivity against lethal ZIKV infection in vivo. These findings suggest that the potent and protective antibody response against ZIKV can be generated within relative short term with high germline identity which provide great hope and promise for successful vaccine development against ZIKV. with Dengue virus (DENV). Site-directed mutagenesis identified two residues 36 within  chain, N31 and S91 that are essential to the functional maturation. The 37 dynamic features unveiled here will assist us to better understand the 38 pathogenesis of ZIKV infection and inform rational design of vaccines. In this study, we applied long-read next-generation sequencing (NGS) and separate NGS runs on the Ion S5 GeneStudio platform (S1 Table) . The Antibodyomics 2.0 pipeline was used to process, annotate, and analyze the 141 NGS data, rendering 1.3 to 2.9 million reads per time point (S1 Table) . Of these 142 sequences, 55.3% to 71.2% are high-quality, full-length antibody variable 143 regions which were used for the analyses of B cell repertoire profiles (S1 Table) . left). In contrast, some specific germline genes were noticed with low frequency, 151 such as IGHV1-8, the V H germline gene of ZK2B10, ranging from 0.98% to 4.80% 152 in seven time points (Fig 1B, left) . The V L germline gene of ZK2B10, 153 corresponding to IGLV1-47, ranging from 2.58% to 5.34% (Fig 1B, right) . which with many derived from common memory B cell clones [19, 47] . 178 Interestingly, the similar pattern has also been reported for an HIV-1 patient 179 undergoing chronic infection in response to a rapidly mutating envelope spike 180 [44]. 181 We next determined changes in the CDR3 loop length. Due to the diversity 182 of the D gene, a rather dispersed distribution in HCDR3 loop length was 183 observed as compared to a steady, canonical CDR3 loop length distribution 184 obtained for  and  chains ( Fig 1D) . The HCDR3 loops were mainly distributed 185 at the range of 9-aa to 15-aa (Fig 1D, left) . As for the light chain, 9-aa KCDR3 186 loops accounted for 79.3% to 88.2% of the  chain repertoire, while 9-aa to 11- Nonetheless, our data suggests that ZK2B10 lineage antibodies were induced 211 rapidly and transiently at the end of acute phase during ZIKV infection. Interestingly, the majority of ZK2B10 somatic variants showed a germline 213 divergence of less than 5.0% in both heavy and  chain repertoires ( confirming that this germline-like mAb lineage emerged at the peak of 265 plasmablast response. According to the alignment compared to IGHV1-8 266 germline sequence, the functional loss of 2H-2, -3 and -14 could be explained 267 potentially by the mutation of D39 located toward the end of HCDR1 (Fig 3A) . 268 As for 11 synthesized ZK2B10-like  chains, 7 (2L-1, -2, -3, -6, -8, -9, and -11) 269 were expressible when paired with WT ZK2B10 heavy chain. Surprisingly, 5 270 (2L-1, -3, -8, -9, and -11) of these 7  variants failed to bind ZIKV E or E DIII 271 combined with undetectable neutralizing activities against ZIKV (Fig 4B) . (Fig 4D) . The RNA load in these groups was suppressed in blood 307 with distinguishable level from the MERS-4 group (Fig 4F) . Exceptionally, 2H-15 308 2, -3 and -14 failed to offer any protection with a median survival time of 7.25 309 to 8 days after ZIKV challenge (Fig 4D) . The viral RNA levels measured in mice 310 treated by them were 3.72 to 4.45 log 10 greater on average than the ZK2B10 311 group on day 5 after ZIKV challenge, respectively (Fig 4F) . In contrast, all of Critical residues for ZK2B10 functional maturation 319 To the further investigation of the maturation pathway of the ZK2B10 lineage, 320 we performed reverse mutagenesis and structural analysis to identify 'hotspot' 321 residues. Before that, we aligned the amino acid sequences of representative 322 ZK2B10 heavy and  chain variants with their putative germline genes, IGHV1-323 8 and IGLV1-47, respectively (Fig 3) . For heavy chain, 2H-2, 2H-3, and 2H-14 324 lose their potency to ZIKV both in vitro and in vivo. These 3 heavy chains 325 possess a single substitution mutation at the D39 with respect to their germline 326 gene (Fig 3A) . To test that, we conducted reverse mutagenesis on 2H-2 (A39D), (Fig 3B) . One such mutation, located on the 343 LCDR1 loop, is N31, which is shared by the weak-functional variants 2L-2 and 344 2L-6, as well as WT ZK2B10  chain (Fig 3B) . The other is at position 91 on 345 LCDR3 loop, which is S91 in WT ZK2B10  chain but predominantly A91 in all 346 these weak-or non-functional  chain variants (Fig 3B) . Thus, N31N and S91 347 could be the critical mutations for ZK2B10  chain maturation. We first 348 examined the effect of these two mutations individually by performing site-349 directed mutagenesis on 2L-1, which is 100% identical to germline gene 350 IGLV1-47. Neither S31N nor A91S could effectively render the germline 351 antibody functional (Fig 5B) . We then introduced a double mutation 17 352 (S31N+A91S) into 2L-1, which, as expected, bound to ZIKV E and E DIII with 353 high affinity and potently neutralized ZIKV at the same level of WT ZK2B10 (Fig 354 5B ). As shown by the crystal structure, 5 residues within ZK2B10  chain (N31, 355 N32, Y33, R51, D94 and L96) directly involved in the in the contact interface 356 [31]. For the two identified critical residues, N31 directly interacts with T309 on 357 ZIKV E DIII, while S91 forms a hydrogen bond with N32, which interacts with 358 T335 on ZIKV E DIII (Fig 5D) . In brief, our combined analyses of NGS data, 359 antibody functions, and complex structure confirm that residues N31 and S91 Committee of Tsinghua University (16-ZLQ9). Acknowledgements 569 We are grateful to the ZIKV convalescent patient for donating his blood samples 570 from which mAbs were isolated and Drs. Jiang Wang, Wenxin Hong, and 571 Lingzhai Zhao for providing the patient with treatment and care. We thank Drs. The authors declare that they have no competing interests. Zika virus pathogenesis and tissue tropism Zika virus (I). isolations and serological 589 specificity Zika virus Zika virus: history, emergence, biology, and prospects for control Zika virus: history of a newly emerging arbovirus Excretion of infectious Zika 599 virus in urine Zika virus infection in pregnant women in Rio de Janeiro Congenital Zika virus syndrome in Brazil: a case series of the 606 first 1501 livebirths with complete investigation Zika virus and 609 birth defects-reviewing the evidence for causality Zika virus infection complicated by Guillain-Barré syndrome -case report Assessing 616 the global threat from Zika virus Antibody-mediated neutralization of flaviviruses: a 619 reductionist view Human antibodies to the dengue virus E-dimer epitope have 623 therapeutic activity against Zika virus infection The antigenic structure of Zika virus and its relation to 626 other flaviviruses: implications for infection and immunoprophylaxis Neutralizing human monoclonal antibodies prevent Zika virus 630 infection in macaques Zika virus: immunity and vaccine development Molecular mechanisms of antibody-mediated 635 neutralisation of flavivirus infection Recurrent potent human neutralizing antibodies to Zika virus in Brazil and 639 Zika 641 virus activates de novo and cross-reactive memory B cell responses in dengue-642 experienced donors cross-reactivity, and function of antibodies elicited by Zika virus 646 infection Molecular determinants of 648 human neutralizing antibodies isolated from a patient infected with Zika virus Neutralization of Zika 651 virus by germline-like human monoclonal antibodies targeting cryptic epitopes 652 on envelope domain III Structural basis of Zika virus-specific antibody protection Delineating antibody 658 recognition against Zika virus during natural infection Structural basis of potent Zika-dengue virus antibody cross-662 neutralization Neutralizing human antibodies prevent Zika virus replication and fetal disease 665 in mice A 667 human antibody against Zika virus crosslinks the E protein to prevent infection Recognition determinants of broadly neutralizing human 671 antibodies against dengue viruses A new class of highly potent, broadly neutralizing antibodies isolated from 675 viremic patients infected with dengue virus A single injection of human 678 neutralizing antibody protects against Zika virus infection and microcephaly in 679 developing mouse embryos Structural basis for 682 neutralization and protection by a Zika virus-specific human antibody Zika virus vaccines Zika vaccine enters clinical trials Toward a 689 more accurate view of human B-cell repertoire by next-generation sequencing, 690 unbiased repertoire capture and single-molecule barcoding Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. Front 695 Immunol Accelerating next-generation vaccine development for global disease 33 698 prevention Quake 700 SR. The promise and challenge of high-throughput sequencing of the antibody 701 repertoire Toward a human vaccines project Focused 705 evolution of HIV-1 neutralizing antibodies revealed by structures and deep 706 sequencing Maturation and diversity of the VRC01-antibody lineage over 15 years of 710 chronic HIV-1 infection A prominent site of antibody vulnerability on HIV envelope incorporates a motif 714 associated with CCR5 binding and its camouflaging glycans Somatic 717 populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 718 pyrosequencing and bioinformatics B-cell responses to an HIV-1 trimer vaccine revealed by unbiased longitudinal 722 repertoire analysis Key gp120 glycans pose 724 roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-725 infected Chinese donor Mining the 728 antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing 729 and phylogenetic pairing of heavy/light chains De novo 732 identification of VRC01 class HIV-1-neutralizing antibodies by next-generation 733 sequencing of B-cell transcripts The emergence of Zika virus and its new clinical 736 syndromes Characterization of a model of lethal dengue virus 2 infection in C57BL/6 739 mice deficient in the alpha/beta interferon receptor Flavivirus NS1 protein in 35 742 infected host sera enhances viral acquisition by mosquitoes Potent 745 neutralization of MERS-CoV by human neutralizing monoclonal antibodies to 746 the viral spike glycoprotein A human inferred germline antibody binds to an immunodominant 750 epitope and neutralizes Zika virus Lower IgG somatic 754 hypermutation rates during acute dengue virus infection is compatible with a 755 germinal center-independent B cell response 758 Longitudinal analysis reveals early development of three MPER-directed 759 neutralizing antibody lineages from an HIV-1-infected individual A plant-produced vaccine 762 protects mice against lethal West Nile virus infection without enhancing Zika or 763 dengue virus infectivity. Vaccine Structures of 766 the Zika virus envelope protein and its complex with a flavivirus broadly 767 protective antibody The 770 3.8 Å resolution cryo-EM structure of Zika virus Hidden 773 lineage complexity of glycan-dependent HIV-1 broadly neutralizing antibodies 774 uncovered by digital panning and native-like gp140 trimer